SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as am...
Personalized subscribers grew 136% YoY, reflecting a fundamental shift towards precision medicine. Despite declining gross margins, HIMS achieved 13pp of operating leverage in Q1. This is by far HIMS' best quarter to date. The markets need to put some respect on Andrew Dudum and his world-class team.
Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo Nordisk partnership. Despite trading at a high valuation, technical indicators suggest continued short-term momentum, with potential for a pullback near February highs. The company's evolution from a telehealth startup to a health-tech giant showcases its strong growth, pr...
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Se...
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to ...
Hims & Hers (HIMS 5.21%) CEO Andrew Dudum isn't interested in taking insurance onto his platform, and that shows how disruptive the company could be. This could be the next great growth stock if Dudum's plans to aggregate demand play out as hoped.
Following the company's first-quarter earnings report, shares of Hims & Hers Health (HIMS 5.21%) opened the following day considerably lower, only to sprint higher once trading began. This action is just one example of why the stock is a bit of a divisive name among investors.
Management's 2030 guidance includes $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, focusing on personalized healthcare and geographic expansion. Anticipating management's guidance for 2025 and 2030, Hims & Hers could be undervalued by up to 62%. Apart from the guidance, the company needs to achieve growth rates in the mid-teens% to justify the current valuation.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.